PetMeds Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Restricted shares require continued employment to vest, while performance units depend on shareholder-return targets.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PetMeds (PETS) granted equity awards to two newly hired executives as employment inducements under its 2024 Inducement Incentive Plan. CEO and President Jeff Willard received 250,000 restricted shares and 250,000 performance share units on September 28, 2026. Chief Technology Officer Andrew Parry received 100,000 restricted shares on October 1, 2026. Restricted shares vest over three years; performance units depend on relative shareholder returns.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- None.
Negative
- Moderate point250,000 restricted shares granted to CEO Jeff Willard add equity compensation for existing shareholders.
- Moderate point250,000 performance share units granted to Willard each carry a contingent right to one common share.
- Minor point100,000 restricted shares granted to CTO Andrew Parry add equity compensation for existing shareholders.
Key Figures
- CEO restricted stock award
- 250,000 shares
- Grant to Jeff Willard
- CEO performance share units
- 250,000 PSUs
- Grant to Jeff Willard
- CTO restricted stock award
- 100,000 shares
- Grant to Andrew Parry
- Restricted stock vesting
- Three equal one-third increments
- Over three years, subject to continued employment
- PSU share entitlement
- One common share per PSU
- Contingent on achieving predetermined relative total shareholder return levels
- PSU performance period
- Three years
- Ends September 27, 2029
Historical Context
-
Employment agreement disclosed the same restricted-share and PSU quantities tied to three-year relative TSR.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
DELRAY BEACH, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced that PetMeds recently granted equity awards previously approved by its Board of Directors to two newly hired executives as a material inducement to employment.
On September 28, 2026, PetMeds granted Jeff Willard, Chief Executive Officer and President, 250,000 shares of restricted common stock and 250,000 performance share units (“PSUs”), and on October 1, 2026, PetMeds granted Andrew Parry, Chief Technology Officer, 100,000 shares of restricted common stock.
The awards were granted pursuant to PetMeds’ 2024 Inducement Incentive Plan, as amended and restated, which was adopted by the Board of Directors in September 2024 and amended in September 2026. The restricted stock awards will vest over three years in equal one-third increments on each of the first three (3) anniversaries of the grant date, subject to continued employment with the Company on each vesting date. The PSUs granted to Mr. Willard each represent a contingent right to receive one share of the Company's common stock if predetermined levels of the Company's total shareholder return relative to the S&P 600 Specialty Retail Index are achieved over a three-year performance period ending on September 27, 2029. The awards were granted as a material inducement to employment with PetMeds, in accordance with Nasdaq Listing Rule 5635(c)(4).
About PetMeds
Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness, pets and pet parents, and the veterinarians who serve them. Through its PetMeds family of brands and through its PetCareRx subsidiary, the Company offers a comprehensive range of pet health solutions — including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com.
Investor Contact
ICR, LLC
Reed Anderson
investor@petmeds.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When do PetMeds executives' restricted stock awards vest?
The restricted stock awards vest in equal one-third increments on the first three anniversaries of each grant date, subject to continued employment on each vesting date.